Merck to stop Phase 3 trial of Lynparza drug in colorectal cancer for futility

U.S.-pharma giant Merck (NYSE:MRK) will end a Phase 3 trial evaluating its Lynparza cancer drug for the treatment of colorectal cancer.
The company "will stop for futility the Phase 3 LYNK-003 trial investigating LYNPARZA with or without bevacizumab